ClinicalTrials.gg
CompletedNCT01878474Updated Jun 17, 2013

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects

A Phase 1 interventional study of TA-8995 and TA-8995 in Dyslipidemia, sponsored by Mitsubishi Tanabe Pharma Corporation. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-17.

Sponsored by Mitsubishi Tanabe Pharma Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing TA-8995 in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. TA-8995 · Dyslipidemias.

Enrollment
10th of 14
96 · median 116
Started
2008
the only one that year
Phase 1
5 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
2 of 14
Mitsubishi Tanabe Pharma Corporation

Among the 14 studies testing TA-8995 in Dyslipidemias, this one is the 10th largest by enrollment, is the only one that started in 2008, is one of 5 in phase 1, and was the 1st registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 14 studies testing TA-8995 in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About TA-8995

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing TA-8995 in Dyslipidemias, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of single doses of TA-8995 in healthy Caucasian and Japanese volunteers.

03

Conditions studied

  • Dyslipidemia

Browse trials for

Keywords

  • MT-8995
  • Dyslipidemia
  • Cholesteryl ester transfer proteins
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caucasian men aged 18-55 years and ≥65 years
  • Women of non-
  • Japanese men aged 18-55 years
  • Subjects were deemed healthy on the basis of medical history, physical examination, (ECG), vital signs and safety tests of blood and urine
  • Subjects were able to give fully informed written consent

Exclusion criteria

Exclusion Criteria:

  • HDL-C level ≥2.59 mmol/L
  • Abnormal Holter
  • Family history of long syndrome, hypokalaemia or Torsade de Pointes
  • Vital signs or 12-lead ECG values outside the acceptable range
  • Positive tests for and C, 1 and 2
  • Positive urine pregnancy test (women only)
  • Severe adverse reaction or allergy to any drug
  • Drug or alcohol abuse
  • Smoking within the 6 months before dosing with TA-8995 (Caucasian subjects), or smoking more than 10 cigarettes daily (Japanese subjects)
  • Over-the-counter or prescribed medication up to 7 days or 5 half-lives (whichever was longer) before dosing with TA-8995
  • Consuming food or drinks containing grapefruit or cranberry within the 7 days before dosing
  • Participation in other clinical trials, or loss of more than 450 mL blood within the previous 3 months
  • abnormal findings at the screening assessment
  • Clinically relevant abnormal medical history or concurrent medical condition
  • Possibility that volunteer would not cooperate
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Single ascending dose in Caucasian men

    Drug: TA-8995

  • Experimental
    Age-effect in Caucasian men

    Drug: TA-8995

  • Experimental
    Gender-effect in Caucasian women

    Drug: TA-8995

  • Experimental
    Single ascending dose in Japanese men

    Drug: TA-8995

  • Placebo comparator
    Placebo: Single ascending dose in Caucasian men

    Drug: Placebo

  • Placebo comparator
    Placebo: Age-effect in Caucasian men

    Drug: Placebo

  • Placebo comparator
    Placeo: Gender-effect in Caucasian women

    Drug: Placebo

  • Placebo comparator
    Placebo: Single ascending dose in Japanese men

    Drug: Placebo

Interventions

  • TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg

  • Drug: TA-8995 25 mg

  • Drug: TA-8995 25 mg

  • Drug: TA-8995 25, 50, 100 and 150 mg

  • DrugPlacebo

    Single ascending dose in Caucasian men

  • DrugPlacebo

    Age-effect in Caucasian men

  • DrugPlacebo

    Gender-effect in Caucasian women

  • DrugPlacebo

    Single ascending dose in Japanese men

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Time frame: 336 hours post dose

  2. Laboratory tests (haematology, biochemistry and urinalysis)

    Time frame: 336 hours post dose

  3. Vital signs (supine systolic and diastolic blood pressure, heart rate and body temperature)

    Time frame: 336 hours post dose

  4. Peak concentration (ng/mL) of TA-8995

    Time frame: 336 hours post dose

  5. Time of peak concentration (hr) of TA-8995

    Time frame: 336 hours post dose

  6. Area under the concentration-time curve (mg/L・hr) up to 24 h (AUC0-24), 72 h (AUC0-72), 168 h (AUC0-168), 336 h (AUC0-336) and infinity (AUC0-∞) of TA-8995

    Time frame: 336 hours post dose

Secondary outcomes

  1. Plasma Cholesterol Ester Transfer Protein (CETP) activity (%) and concentration (mg/mL)

    Time frame: 336 hours post dose

07

Study locations

1 site
  • Hammersmith Medicines Research (HMR)
    London, NW10 7EW, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2013
First posted
Jun 17, 2013
Start
Mar 2008
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Last update
Jun 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01878474
Responsible party
Sponsor
First posted
Jun 17, 2013
Start date
Mar 2008
Primary completion
Jun 2009
Completion
Jun 2009
Last update
Jun 17, 2013

Study contacts

Steve Warrington, MA MD FRCP FFPM
principal investigator · Hammersmith Medicines Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TA-8995

Start the discussion